InterCure Expects Positive EBITDA for 2025
Adjusted EBITDA is expected to be positive in both the first and second halves of 2025, marking the Company's twelfth consecutive half-year of positive Adjusted EBITDA. Cash on hand of NIS 43M as of December 31, 2025. Alexander Rabinovich, CEO noted: "2025 marked a year of disciplined execution and renewed growth for InterCure. We delivered meaningful acceleration in the second half of the year with nearly 20% revenue growth and achieved our twelfth consecutive half-year of positive Adjusted EBITDA. The anticipated commencement of operations under the Botanico transaction and our strategic collaboration with Cannasoul are expected to further strengthen our pharmaceutical platform and global positioning. This marks another key milestone with our first significant revenues in the German market, as we expect continued execution of our global expansion strategy in Germany and additional markets throughout 2026. As regulatory frameworks continue to evolve, particularly in the United States and Europe, we believe InterCure is strategically positioned to leverage its vertically integrated model, scientific leadership, and international partnerships to drive long-term value for patients and shareholders."
Trade with 70% Backtested Accuracy
Analyst Views on INCR
About INCR
About the author
InterCure Receives Noncompliance Notice from Nasdaq
- Noncompliance Notice: InterCure received a noncompliance notice from Nasdaq last week, indicating that the company has failed to meet certain listing requirements, which could impact stock trading stability and investor confidence.
- Potential Consequences: This notice may expose the company to the risk of delisting, affecting its ability to raise funds and its market reputation, especially as investor scrutiny on compliance increases in the current market environment.
- Response Measures: InterCure must implement effective measures to address the noncompliance issues, including potential financial restructuring or improving corporate governance to ensure adherence to Nasdaq's listing standards.
- Market Reaction: Investor reactions to this news may lead to stock price volatility, with potential selling pressure in the short term, thereby impacting the company's market capitalization and future financing plans.
InterCure Receives Nasdaq Compliance Notice
- Compliance Notice: InterCure received a written notice from Nasdaq indicating non-compliance with listing rules due to its ordinary shares closing bid price being below $1.00 for the last 30 consecutive business days.
- Compliance Period: The company has been granted a 180-calendar-day compliance period until August 24, 2026, allowing it time to regain compliance with the minimum bid price requirement, which is crucial for maintaining its listing status.
- Subsequent Measures: If compliance is not achieved by the deadline, InterCure expects to be eligible for an additional 180-calendar-day compliance period, providing further opportunity to improve its stock price performance.
- Market Impact: This compliance notice may negatively affect investor confidence, particularly as the company faces stock price pressure, potentially impacting its ability to raise funds and its market image.
Trump's Marijuana Reclassification Expected to Propel This Cannabis ETF: Significant Momentum Increase
Trump's Executive Order Impact: A leveraged ETF focused on the American cannabis industry is expected to rise following President Trump's executive order aimed at easing federal restrictions on cannabis.
AdvisorShares MSOS Daily Leveraged ETF: The AdvisorShares MSOS Daily Leveraged ETF has seen a significant increase in its Momentum score, indicating strong investor interest amid regulatory changes, despite a recent pullback in its value.
Market Volatility: The fund experienced a notable decline of 50.59% after a previous drop of 26.91%, attributed to uncertainties regarding banking regulations in Trump's order, which were anticipated by the industry.
Overall Market Sentiment: Despite a high Momentum score, the ETF faces unfavorable price trends in the short, medium, and long term, reflecting mixed market sentiment towards cannabis stocks.
InterCure Joins High-End US Cannabis Market Through ISHI Agreement
InterCure's Acquisition of Botanico: InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI) to enhance its global cannabis portfolio, gaining access to advanced cultivation technologies and brand partnerships in the U.S. cannabis market.
Regulatory Context and Future Plans: The acquisition coincides with potential regulatory changes regarding cannabis scheduling in the U.S., and InterCure plans to complete the deal by Q1 2026, pending approvals, while integrating ISHI's leadership and assets.
InterCure Reveals Strategic Purchase of ISHI, Gaining Access to Top U.S. Cannabis Technology and Brands
InterCure's Strategic Acquisition: InterCure Ltd. has announced the acquisition of Botanico Ltd. (ISHI), a premium medical cannabis technology and brand company, enhancing its access to advanced cultivation technologies and partnerships with leading U.S. cannabis operators.
Regulatory Momentum and Market Potential: The acquisition coincides with the Trump administration's exploration of cannabis rescheduling, which could create significant opportunities for international cannabis companies like InterCure, positioning them to capitalize on the evolving U.S. cannabis landscape.
InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
Leadership Change at InterCure: Mr. Ehud Barak will resign as Chairman of InterCure's board on February 13, 2025, with Mr. Alexander Rabinovich taking over after successfully leading the company as CEO for five years.
Company Recovery Efforts: InterCure is focused on restoring its Nir Oz facility, re-launching existing products, and expanding its pharmaceutical cannabis portfolio to better serve patient needs.
InterCure Receives Noncompliance Notice from Nasdaq
- Noncompliance Notice: InterCure received a noncompliance notice from Nasdaq last week, indicating that the company has failed to meet certain listing requirements, which could impact stock trading stability and investor confidence.
- Potential Consequences: This notice may expose the company to the risk of delisting, affecting its ability to raise funds and its market reputation, especially as investor scrutiny on compliance increases in the current market environment.
- Response Measures: InterCure must implement effective measures to address the noncompliance issues, including potential financial restructuring or improving corporate governance to ensure adherence to Nasdaq's listing standards.
- Market Reaction: Investor reactions to this news may lead to stock price volatility, with potential selling pressure in the short term, thereby impacting the company's market capitalization and future financing plans.
InterCure Receives Nasdaq Compliance Notice
- Compliance Notice: InterCure received a written notice from Nasdaq indicating non-compliance with listing rules due to its ordinary shares closing bid price being below $1.00 for the last 30 consecutive business days.
- Compliance Period: The company has been granted a 180-calendar-day compliance period until August 24, 2026, allowing it time to regain compliance with the minimum bid price requirement, which is crucial for maintaining its listing status.
- Subsequent Measures: If compliance is not achieved by the deadline, InterCure expects to be eligible for an additional 180-calendar-day compliance period, providing further opportunity to improve its stock price performance.
- Market Impact: This compliance notice may negatively affect investor confidence, particularly as the company faces stock price pressure, potentially impacting its ability to raise funds and its market image.
Trump's Marijuana Reclassification Expected to Propel This Cannabis ETF: Significant Momentum Increase
Trump's Executive Order Impact: A leveraged ETF focused on the American cannabis industry is expected to rise following President Trump's executive order aimed at easing federal restrictions on cannabis.
AdvisorShares MSOS Daily Leveraged ETF: The AdvisorShares MSOS Daily Leveraged ETF has seen a significant increase in its Momentum score, indicating strong investor interest amid regulatory changes, despite a recent pullback in its value.
Market Volatility: The fund experienced a notable decline of 50.59% after a previous drop of 26.91%, attributed to uncertainties regarding banking regulations in Trump's order, which were anticipated by the industry.
Overall Market Sentiment: Despite a high Momentum score, the ETF faces unfavorable price trends in the short, medium, and long term, reflecting mixed market sentiment towards cannabis stocks.
InterCure Joins High-End US Cannabis Market Through ISHI Agreement
InterCure's Acquisition of Botanico: InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI) to enhance its global cannabis portfolio, gaining access to advanced cultivation technologies and brand partnerships in the U.S. cannabis market.
Regulatory Context and Future Plans: The acquisition coincides with potential regulatory changes regarding cannabis scheduling in the U.S., and InterCure plans to complete the deal by Q1 2026, pending approvals, while integrating ISHI's leadership and assets.
InterCure Reveals Strategic Purchase of ISHI, Gaining Access to Top U.S. Cannabis Technology and Brands
InterCure's Strategic Acquisition: InterCure Ltd. has announced the acquisition of Botanico Ltd. (ISHI), a premium medical cannabis technology and brand company, enhancing its access to advanced cultivation technologies and partnerships with leading U.S. cannabis operators.
Regulatory Momentum and Market Potential: The acquisition coincides with the Trump administration's exploration of cannabis rescheduling, which could create significant opportunities for international cannabis companies like InterCure, positioning them to capitalize on the evolving U.S. cannabis landscape.
InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
Leadership Change at InterCure: Mr. Ehud Barak will resign as Chairman of InterCure's board on February 13, 2025, with Mr. Alexander Rabinovich taking over after successfully leading the company as CEO for five years.
Company Recovery Efforts: InterCure is focused on restoring its Nir Oz facility, re-launching existing products, and expanding its pharmaceutical cannabis portfolio to better serve patient needs.
